Skip to main content
Institutional deep-dive - valuation, health, statements

Financial Analysis

Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data

Fundamentals

908 Devices Inc. MASS

· Healthcare · Laboratory Analytical Instruments

FY2025 10-K, filed 2026-03-09
SEC EDGAR

Filing evidence summary

Mixed evidenceCoverage 4/5 core metrics

Latest reported free cash flow was -$25M.

Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.

Evidence signals

  • Free cash flow was negative

    Latest reported free cash flow was -$25M.

    Why this surfaced

    Free cash flow = operating cash flow minus capital expenditures; positive is supporting evidence, not a valuation conclusion. Period end 2025-12-31.

  • 5 filing risk checks flagged

    Flagged areas: Earnings quality, Solvency & liquidity, Dilution.

    Why this surfaced

    The full financial analysis shows each value, threshold, and sector limitation.

  • Revenue expanded

    Latest reported annual revenue changed +17.7% from the prior reported annual observation.

    Why this surfaced

    Direction threshold: above +2% constructive; below -2% caution; otherwise monitor. This is not labeled one-year growth when filing periods have a gap. Period end 2025-12-31.

  • Operating margin improved

    Operating margin changed +50.1 percentage points from the prior annual period.

    Why this surfaced

    Direction threshold: more than +1 percentage point constructive; below -1 point caution. Period end 2025-12-31.

Core trend metrics

Latest annual revenue growth
+17.7%
as of 2025-12-31
Latest annual operating margin
-70.1%
as of 2025-12-31
Free cash flow
-$25M
as of 2025-12-31
ROIC snapshot
-22.0%
period varies

Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.

Where to look next

Risk checks

5of 12 rule-based checks flagged
  • Earnings quality
  • Solvency & liquidity
  • Dilution

Financial movement

  • Cash→ flat
  • Long-term debt→ flat
  • Inventory→ flat
  • Receivables→ flat
  • Current assets→ flat

Source & freshness

Source
SEC EDGAR XBRL
Fetched
2026-09-06
Latest period end
2025-12-31
Filings
EDGAR ↗

Reported segment mix

figures as filed · share of the filed sum · change vs the prior period in the same filing
Fiscal year ending 2025-12-3110-K filed 2026-03-09prior period 2024-12-31 from the same filingView filing
By business segment
Revenue
  • Single Reportable Segment$56.2M
    100.0%
    +17.7% yoy

Members sum to the consolidated $56.2M for this period.

By product or service
Revenue
  • Product$43.3M
    share n/a
    +21.8% yoy
  • Device Sales$36.7M
    share n/a
    +15.7% yoy
  • Recurring$19.4M
    share n/a
    +21.9% yoy
  • Service$12.9M
    share n/a
    +5.7% yoy
  • Contract$117K
    share n/a
    -11.4% yoy

member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.

By geography
Revenue
  • United States$41.2M
    73.4%
    +15.7% yoy
  • EMEA$10.4M
    18.6%
    +14.2% yoy
  • Asia Pacific$3M
    5.3%
    +42.5% yoy
  • Americas Other$1.52M
    2.7%
    +76.7% yoy

Members sum to the consolidated $56.2M for this period.

Latest quarter
Quarter ending 2026-03-3110-Q filed 2026-05-06prior period 2025-03-31 from the same filingView filing
  • Single Reportable Segment$13.4M
    100.0%
    +13.6% yoy

Change is against the same quarter a year earlier, as reported in the same 10-Q.

Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.

Peer percentiles

latest fiscal year ending 2025-12-31 · among 4,003 US-listed filers · 318 in Healthcare
MetricValuevs all filersvs sector
Revenue
latest fiscal-year revenue as filed
$56M
22ndof 3,301
bottom third
29thof 291
bottom third
Revenue growth
latest fiscal-year revenue vs the prior fiscal year
17.7%
74thof 3,137
top third
72ndof 277
top third
Gross margin
gross profit ÷ revenue
50.6%
67thof 1,603
middle third
42ndof 212
middle third
Operating margin
operating income ÷ revenue
-70.2%
18thof 2,819
bottom third
20thof 280
bottom third
Net margin
net income ÷ revenue
34.7%
92ndof 3,263
top third
99thof 290
top third
Free-cash-flow margin
(operating cash flow − |capex|) ÷ revenue
-43.9%
16thof 2,679
bottom third
21stof 261
bottom third
Return on equity
net income ÷ stockholders' equity (positive equity only)
13.6%
77thof 3,576
top third
82ndof 291
top third
Stock comp ÷ revenue
stock-based compensation ÷ revenue · lower is ranked higher
17.5%
17thof 2,895
bottom third
16thof 272
bottom third
Days sales outstanding
receivables ÷ revenue × 365 · lower is ranked higher
74 days
24thof 2,398
bottom third
24thof 266
bottom third

Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.

Earnings quality

Not available for MASS yet: Earnings-quality fields arrive with this issuer's next re-crawl (sec_screen_v6)..

Point-in-time ledger

Not available for MASS yet: The point-in-time ledger arrives with this issuer's next re-crawl (sec_screen_v6)..

Notes by disclosure type

Not available for MASS yet: no footnote text blocks on file for this filer in the ingested DERA files.

Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.

Educational content only. Not financial advice. TrendNalysis provides educational and informational financial analysis built from public SEC filings and economic data (FRED, BLS). It is not financial, investment, tax, or legal advice and is not a recommendation to buy or sell any security. Market pricing is not currently included. Past performance does not guarantee future results. Always do your own research and consult a licensed financial professional before investing.